Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523 | Director | June 05, 2026 | June 15, 2026 |
| Arcturus Therapeutics Ltd.ARCT · Entity 160417 | Director | January 01, 2019 | January 02, 2019 |
| Evolus, Inc.EOLS · Entity 5341 | Director | January 27, 2023 | February 01, 2023 |
| RESMED INCRMD · Entity 2692 | Director | September 02, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcturus Therapeutics Holdings Inc.
Report date June 05, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2036-06-05 | Direct | 15,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 15,000 · Balance 15,000 F1: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
Arcturus Therapeutics Ltd.
Report date January 01, 2019 · Filed January 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 86,452 |
Reported balance
Holding disclosure · report date 2019-01-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 86,452 F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. F2: Vesting monthly over a two year period from August 24, 2018. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. F3: Vesting monthly over a one year period from August 24, 2018. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019.
F2: Vesting monthly over a two year period from August 24, 2018.
F3: Vesting monthly over a one year period from August 24, 2018.
Evolus, Inc.
Report date January 27, 2023 · Filed February 01, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,174 |
Reported balance
After 2023-01-27 transaction · row 1
1 source rowRow 1 · 2023-01-27 · Grant · Acquired 8,293 · Balance 43,174 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of January 27, 2023, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.25 · Expires 2033-01-27 | Direct | 11,789 |
Reported balance
After 2023-01-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-27 · Grant · Acquired 11,789 · Balance 11,789 F2: The shares subject to the option will vest over a period of twelve months, with 1/12th of the shares subject to the option vesting monthly on the anniversary of January 27, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 10,000 |
Reported balance
Holding disclosure · report date 2023-01-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of January 27, 2023, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer
F2: The shares subject to the option will vest over a period of twelve months, with 1/12th of the shares subject to the option vesting monthly on the anniversary of January 27, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.
RESMED INC
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 51,803 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 970 · Balance 51,803 F1: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NUVASIVE INC
Report date May 03, 2018 · Filed May 07, 2018
Section 16 reporting ended · disclosed 2018-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectFamily Trust | 36,713 |
Last balance in matching sequence
After 2018-05-03 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2018-05-03 · Exercise / conversion · Acquired 16,844 · Balance 35,490 F1: On May 3, 2018, the Reporting Person retired from his position as a member of the Issuer's Board of Directors. Pursuant to deferral elections made by the Reporting Person, all shares underlying Restricted Stock Units ("RSUs") subject to such deferrals were delivered to the Reporting Person promptly following the Issuer's 2018 Annual Meeting of Stockholders on May 3, 2018, the date on which the Reporting Person retired. F2: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Row 2 · 2018-05-03 · Exercise / conversion · Acquired 6,000 · Balance 41,490 F2: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. Row 3 · 2018-05-03 · Tax withholding · Disposed 4,777 · Balance 36,713 F3: Payment of exercise price by Issuer's withholding of shares incident to the respective option exercise. F2: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-03 · Exercise / conversion · Disposed 2,833 · Balance 0 F4: This RSU award was granted to the Reporting Person on May 24, 2012 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-05-03 · Exercise / conversion · Disposed 2,833 · Balance 0 F5: This RSU award was granted to the Reporting Person on May 23, 2013 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-03 · Exercise / conversion · Disposed 3,725 · Balance 0 F6: This RSU award was granted to the Reporting Person on May 22, 2014 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-05-03 · Exercise / conversion · Disposed 2,501 · Balance 0 F7: This RSU award was granted to the Reporting Person on June 12, 2015 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-05-03 · Exercise / conversion · Disposed 2,822 · Balance 0 F8: This RSU award was granted to the Reporting Person on May 19, 2016 and is fully vested. |
| RSUsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-05-03 · Exercise / conversion · Disposed 2,130 · Balance 0 F9: This RSU award was granted to the Reporting Person on May 18, 2017 and is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.45 · Expires 2018-05-22 | Direct | 0 |
Reported balance
After 2018-05-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-05-03 · Exercise / conversion · Disposed 6,000 · Balance 0 F10: The option, representing a right to purchase a total of 6,000 shares, was granted on May 22, 2008 and is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 3, 2018, the Reporting Person retired from his position as a member of the Issuer's Board of Directors. Pursuant to deferral elections made by the Reporting Person, all shares underlying Restricted Stock Units ("RSUs") subject to such deferrals were delivered to the Reporting Person promptly following the Issuer's 2018 Annual Meeting of Stockholders on May 3, 2018, the date on which the Reporting Person retired.
F2: Shares directly held by the Reporting Person. The Reporting Person also holds conditional rights to receive shares pursuant to previously disclosed Company equity awards.
F3: Payment of exercise price by Issuer's withholding of shares incident to the respective option exercise.
F4: This RSU award was granted to the Reporting Person on May 24, 2012 and is fully vested.
F5: This RSU award was granted to the Reporting Person on May 23, 2013 and is fully vested.
F6: This RSU award was granted to the Reporting Person on May 22, 2014 and is fully vested.
F7: This RSU award was granted to the Reporting Person on June 12, 2015 and is fully vested.
F8: This RSU award was granted to the Reporting Person on May 19, 2016 and is fully vested.
F9: This RSU award was granted to the Reporting Person on May 18, 2017 and is fully vested.
F10: The option, representing a right to purchase a total of 6,000 shares, was granted on May 22, 2008 and is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 06, 2017 Filed Nov 8, 2017 21:28 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 20,000 | $27.58 | $551,600.00 |
DisclosureSEC source: 0001140361-17-041597 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 16:54 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-037762 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,460 Underlying: ResMed Common Stock · 20,000 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 16:54 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 20,000 | $77.01 | $1,540,200.00 |
DisclosureSEC source: 0001140361-17-037762 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,800 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 76.38 to 77.34. The price reported above represents the weighted average sales price. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 16:54 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 20,000 | $27.58 | $551,600.00 |
DisclosureSEC source: 0001140361-17-037762 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 21:55 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-034452 · doc1.xml · derivative · entry 4 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,460 Underlying: ResMed Common Stock · 20,000 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 21:55 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,122 | $77.41 | $86,854.02 |
DisclosureSEC source: 0001140361-17-034452 · doc1.xml · nonDerivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,800 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from 77.38 to 77.45. The price reported above represents the weighted average sales price. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 21:55 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 18,878 | $76.70 | $1,447,942.60 |
DisclosureSEC source: 0001140361-17-034452 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,922 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 76.38 to 77.37. The price reported above represents the weighted average sales price. Read SEC document |
| September 05, 2017 Filed Sep 6, 2017 21:55 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 20,000 | $27.58 | $551,600.00 |
DisclosureSEC source: 0001140361-17-034452 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:21 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 6,757 | $74.17 | $501,166.69 |
DisclosureSEC source: 0001140361-17-033105 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,800 F1 · kind: Represents a gift to the Scripps Research Institute, a 501(c)(3) non-profit corporation. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F1 · shares: Represents a gift to the Scripps Research Institute, a 501(c)(3) non-profit corporation. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F2 · price: This transaction was executed in multiple trades at prices ranging from 73.49 to 74.85. The price reported above represents the weighted average sales price. Read SEC document |
| August 04, 2017 Filed Aug 7, 2017 21:25 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-030381 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,460 Underlying: ResMed Common Stock · 20,000 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| August 04, 2017 Filed Aug 7, 2017 21:25 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 20,000 | $75.15 | $1,503,000.00 |
DisclosureSEC source: 0001140361-17-030381 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,557 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 74.69 to 75.44. The price reported above represents the weighted average sales price. Read SEC document |
| August 04, 2017 Filed Aug 7, 2017 21:25 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 20,000 | $27.58 | $551,600.00 |
DisclosureSEC source: 0001140361-17-030381 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 22:13 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-027380 · doc1.xml · derivative · entry 4 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,460 Underlying: ResMed Common Stock · 20,000 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F4 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 22:13 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 400 | $77.15 | $30,860.00 |
DisclosureSEC source: 0001140361-17-027380 · doc1.xml · nonDerivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,557 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · price: This transaction was executed in multiple trades at prices ranging from 76.83 to 77.26. The price reported above represents the weighted average sales price. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 22:13 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 19,600 | $76.49 | $1,499,204.00 |
DisclosureSEC source: 0001140361-17-027380 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,957 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 75.83 to 76.76. The price reported above represents the weighted average sales price. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 22:13 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 20,000 | $27.58 | $551,600.00 |
DisclosureSEC source: 0001140361-17-027380 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 18:44 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-023921 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,460 Underlying: ResMed Common Stock · 20,000 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 18:44 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 20,000 | $72.65 | $1,452,960.00 |
DisclosureSEC source: 0001140361-17-023921 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,557 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 72.43 to 72.79. The price reported above represents the weighted average sales price. Read SEC document |
| June 05, 2017 Filed Jun 6, 2017 18:44 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 20,000 | $27.58 | $551,600.00 |
DisclosureSEC source: 0001140361-17-023921 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| May 18, 2017 Filed May 22, 2017 17:47 UTC | NUVASIVE INC NUVA · Entity 110002 | GrantRSUs · Derivative | 2,130 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-034401 · doc4.xml · derivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,130 Underlying: Common Stock · 2,130 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2018 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2018 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors. Read SEC document |
| May 04, 2017 Filed May 5, 2017 16:38 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-018559 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,460 Underlying: ResMed Common Stock · 20,000 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| May 04, 2017 Filed May 5, 2017 16:38 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 20,000 | $68.75 | $1,374,920.00 |
DisclosureSEC source: 0001140361-17-018559 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,557 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 68.44 to 69.00. The price reported above represents the weighted average sales price. Read SEC document |
| May 04, 2017 Filed May 5, 2017 16:38 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 20,000 | $27.58 | $551,600.00 |
DisclosureSEC source: 0001140361-17-018559 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| April 04, 2017 Filed Apr 6, 2017 17:14 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-015102 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,460 Underlying: ResMed Common Stock · 20,000 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| April 04, 2017 Filed Apr 6, 2017 17:14 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 20,000 | $70.67 | $1,413,360.00 |
DisclosureSEC source: 0001140361-17-015102 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,557 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 70.42 to 71.14. The price reported above represents the weighted average sales price. Read SEC document |
| April 04, 2017 Filed Apr 6, 2017 17:14 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 20,000 | $27.58 | $551,600.00 |
DisclosureSEC source: 0001140361-17-015102 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 20:51 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 3,915 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-17-010999 · doc1.xml · derivative · entry 5 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,460 Underlying: ResMed Common Stock · 3,915 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 20:51 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 16,085 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-17-010999 · doc1.xml · derivative · entry 4 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 16,085 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 20:51 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 20,000 | $71.70 | $1,434,000.00 |
DisclosureSEC source: 0001140361-17-010999 · doc1.xml · nonDerivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,557 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 71.48 to 71.97. The price reported above represents the weighted average sales price. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 20:51 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 3,915 | $27.58 | $107,975.70 |
DisclosureSEC source: 0001140361-17-010999 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 20:51 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 16,085 | $33.70 | $542,064.50 |
DisclosureSEC source: 0001140361-17-010999 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 06, 2017 Filed Feb 7, 2017 20:14 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-17-004829 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,085 Underlying: ResMed Common Stock · 20,000 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| February 06, 2017 Filed Feb 7, 2017 20:14 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 20,000 | $68.32 | $1,366,420.00 |
DisclosureSEC source: 0001140361-17-004829 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,557 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 67.58 to 68.58. The price reported above represents the weighted average sales price. Read SEC document |
| February 06, 2017 Filed Feb 7, 2017 20:14 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 20,000 | $33.70 | $674,000.00 |
DisclosureSEC source: 0001140361-17-004829 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 04, 2017 Filed Jan 5, 2017 22:24 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-17-000783 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,085 Underlying: ResMed Common Stock · 20,000 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| January 04, 2017 Filed Jan 5, 2017 22:24 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 20,000 | $62.14 | $1,242,760.00 |
DisclosureSEC source: 0001140361-17-000783 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,557 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 61.72 to 62.30. The price reported above represents the weighted average sales price. Read SEC document |
| January 04, 2017 Filed Jan 5, 2017 22:24 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 20,000 | $33.70 | $674,000.00 |
DisclosureSEC source: 0001140361-17-000783 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 23, 2016 Filed Dec 27, 2016 20:27 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 9,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-16-090788 · doc1.xml · nonDerivative · entry 4 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,557 F4 · kind: Represents a gift of shares to the Greater Houston Community Foundation. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F4 · price: Represents a gift of shares to the Greater Houston Community Foundation. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| December 23, 2016 Filed Dec 27, 2016 20:27 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-16-090788 · doc1.xml · nonDerivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,407 F3 · kind: Represents a gift of shares to the University of San Diego. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F3 · price: Represents a gift of shares to the University of San Diego. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| December 22, 2016 Filed Dec 27, 2016 20:27 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 2,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-16-090788 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,907 F2 · kind: Represents a gift of shares to Donors Trust, Inc. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F2 · price: Represents a gift of shares to Donors Trust, Inc. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| December 22, 2016 Filed Dec 27, 2016 20:27 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 2,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-16-090788 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,957 F1 · kind: Represents a gift to Mercatus Center, Inc. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F1 · price: Represents a gift to Mercatus Center, Inc. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. Read SEC document |
| December 09, 2016 Filed Dec 13, 2016 00:23 UTC | RESMED INC RMD · Entity 2692 | GiftResMed Common Stock | 34,400 | $61.71 | $2,122,824.00 |
DisclosureSEC source: 0001140361-16-089443 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,007 F1 · kind: The transaction represents a gift to the Farrell Family Foundation, a 501(c)(3) non-profit corporation. Dr. Farrell has no beneficial interest, control or dispositive power over the gifted shares. F2 · price: This transaction was executed in multiple trades at prices ranging from $61.18 to $62.24. The price reported above represents the weighted average sales price. Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 21:49 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-16-088907 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 Underlying: ResMed Common Stock · 20,000 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 21:49 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 20,000 | $59.83 | $1,196,540.00 |
DisclosureSEC source: 0001140361-16-088907 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,407 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 59.59 to 60.05. The price reported above represents the weighted average sales price. Read SEC document |
| December 05, 2016 Filed Dec 6, 2016 21:49 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 20,000 | $33.70 | $674,000.00 |
DisclosureSEC source: 0001140361-16-088907 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 02:53 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 4,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-087152 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,407 F1 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2017, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:16 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-16-085037 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,085 Underlying: ResMed Common Stock · 20,000 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:16 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 20,000 | $57.28 | $1,145,560.00 |
DisclosureSEC source: 0001140361-16-085037 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,978 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 56.92 to 57.44. The price reported above represents the weighted average sales price. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 19:16 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 20,000 | $33.70 | $674,000.00 |
DisclosureSEC source: 0001140361-16-085037 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 17:49 UTC | NUVASIVE INC NUVA · Entity 110002 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001209191-16-148016 · doc4.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2016-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing a right to purchase a total of 6,000 shares, was granted on May 27, 2007 and is fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.